Ensign Peak Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Ensign Peak Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-74,760	Closed	-$323K	–	1763
2023 Q3	$323K	Hold	74,760	–	–	﹤0.01%	1679
2023 Q2	$493K	Hold	74,760	–	–	﹤0.01%	1637
2023 Q1	$508K	Buy	74,760 +21,800	+41%	+$153K	﹤0.01%	1640
2022 Q4	$391K	Buy	52,960 +22,800	+76%	+$222K	﹤0.01%	1673
2022 Q3	$298K	Hold	30,160	–	–	﹤0.01%	1708
2022 Q2	$329K	Hold	30,160	–	–	﹤0.01%	1637
2022 Q1	$341K	Hold	30,160	–	–	﹤0.01%	1709
2021 Q4	$473K	Sell	30,160 -23,140	-43%	-$403K	﹤0.01%	1650
2021 Q3	$914K	Hold	53,300	–	–	﹤0.01%	1466
2021 Q2	$1.15M	Hold	53,300	–	–	﹤0.01%	1392
2021 Q1	$801K	Hold	53,300	–	–	﹤0.01%	1491
2020 Q4	$700K	Hold	53,300	–	–	﹤0.01%	1522
2020 Q3	$515K	Hold	53,300	–	–	﹤0.01%	1525
2020 Q2	$610K	Hold	53,300	–	–	﹤0.01%	1418
2020 Q1	$552K	Buy	53,300 +6,500	+14%	+$80.6K	﹤0.01%	1370
2019 Q4	$768K	Buy	+46,800	New	+$708K	﹤0.01%	1419

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Ensign Peak Advisors's VNDA Position: Q4 2023 in Review

Ensign Peak Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 74,760 shares — an estimated $323K sold.

Ensign Peak Advisors first reported a position in VNDA in Q4 2019 and held it in 16 quarters. The position peaked at $1.15M in Q2 2021. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Ensign Peak Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Ensign Peak Advisors sold 74,760 Vanda Pharmaceuticals shares in Q4 2023, an estimated $323K.
Ensign Peak Advisors first reported a position in Vanda Pharmaceuticals in Q4 2019 and held it in 16 quarters.
Ensign Peak Advisors's Vanda Pharmaceuticals position peaked at $1.15M in Q2 2021.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.